An update on activated protein C (xigris) in the management of sepsis.
作者信息
Alaniz Cesar
机构信息
Dr. Alaniz is a Clinical Pharmacist and Clinical Associate Professor at the University of Michigan Hospitals and College of Pharmacy in Ann Arbor, Michigan.
出版信息
P T. 2010 Sep;35(9):504-29.
Abstract
摘要
相似文献
1
An update on activated protein C (xigris) in the management of sepsis.关于活化蛋白C（Xigris）在脓毒症治疗中的最新进展。
P T. 2010 Sep;35(9):504-29.
2
Activated protein C (Xigris) treatment in sepsis: a drug in trouble.脓毒症中活化蛋白C（Xigris）治疗：一种陷入困境的药物。
Acta Anaesthesiol Scand. 2006 Sep;50(8):907-10. doi: 10.1111/j.1399-6576.2006.01086.x.
3
Twenty-four hour infusion of human recombinant activated protein C (Xigris) early in severe acute pancreatitis: The XIG-AP 1 trial.在重症急性胰腺炎早期进行人重组活化蛋白C（希加曲班）24小时输注：XIG-AP 1试验。
Pancreatology. 2015 Nov-Dec;15(6):635-41. doi: 10.1016/j.pan.2015.10.001. Epub 2015 Oct 20.
4
Recombinant human activated protein C (Xigris).重组人活化蛋白C（Xigris）
Int J Clin Pract. 2002 Sep;56(7):542-5.
5
Administration of human recombinant activated protein C is not associated with pancreatic parenchymal haemorrhage in L-arginine-induced experimental acute pancreatitis.在L-精氨酸诱导的实验性急性胰腺炎中，给予人重组活化蛋白C与胰腺实质出血无关。
JOP. 2013 Nov 10;14(6):610-7. doi: 10.6092/1590-8577/1328.
6
Sepsis update: management of severe sepsis and septic shock in the emergency department after the withdrawal of Xigris.
CJEM. 2012 Sep;14(5):265-9. doi: 10.2310/8000.2012.120769.
7
Recombinant human activated protein C for severe sepsis in neonates.重组人活化蛋白C用于新生儿严重脓毒症
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD005385. doi: 10.1002/14651858.CD005385.pub3.
8
Drotrecogin alfa (activated; Xigris): an effective and cost-efficient treatment for severe sepsis.重组人活化蛋白 C（Xigris）：治疗严重脓毒症的有效且经济有效的方法。
Expert Rev Pharmacoecon Outcomes Res. 2004 Feb;4(1):15-26. doi: 10.1586/14737167.4.1.15.
9
Recombinant factor VII (activated) for haemorrhagic complications of severe sepsis treated with recombinant protein C (activated).重组活化凝血因子VII用于接受重组活化蛋白C治疗的严重脓毒症出血并发症
Acta Haematol. 2006;116(2):126-30. doi: 10.1159/000093643.
10
Activated protein C (Xigris) for severe sepsis.用于严重脓毒症的活化蛋白C（Xigris）
Med Lett Drugs Ther. 2002 Feb 18;44(1124):17-8.
引用本文的文献
1
Neutrophils and the Systemic Inflammatory Response Syndrome (SIRS).中性粒细胞与全身炎症反应综合征（SIRS）。
Int J Mol Sci. 2023 Aug 30;24(17):13469. doi: 10.3390/ijms241713469.
2
The role of extracellular histones in COVID-19.细胞外组蛋白在 COVID-19 中的作用。
J Intern Med. 2023 Mar;293(3):275-292. doi: 10.1111/joim.13585. Epub 2022 Dec 18.
3
Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia Presenting Concomitantly With Purpura Fulminans: A Case Report.严重急性呼吸综合征冠状病毒2型肺炎合并暴发性紫癜：1例报告
Cureus. 2022 Jan 13;14(1):e21188. doi: 10.7759/cureus.21188. eCollection 2022 Jan.
4
The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases.急性和长新冠病毒感染中血栓形成与炎症风暴的相互作用：治疗靶点和临床病例。
Viruses. 2021 Sep 23;13(10):1904. doi: 10.3390/v13101904.
5
Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease.血液疾病患者输血支持中新鲜冰冻血浆、冷沉淀、免疫球蛋白和凝血因子应用的最新进展。
Semin Hematol. 2020 Apr;57(2):73-82. doi: 10.1053/j.seminhematol.2020.07.006. Epub 2020 Jul 27.
6
DAMPs and NETs in Sepsis.脓毒症中的 DAMPs 和 NETs。
Front Immunol. 2019 Oct 30;10:2536. doi: 10.3389/fimmu.2019.02536. eCollection 2019.
7
Activated Protein C in Cutaneous Wound Healing: From Bench to Bedside.活化蛋白 C 在皮肤创伤愈合中的作用：从基础到临床。
Int J Mol Sci. 2019 Feb 19;20(4):903. doi: 10.3390/ijms20040903.
8
Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients.人重组蛋白C用于成人和儿童患者的严重脓毒症及脓毒性休克。
Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD004388. doi: 10.1002/14651858.CD004388.pub6.
9
Trauma is danger.创伤即危险。
J Transl Med. 2011 Jun 15;9:92. doi: 10.1186/1479-5876-9-92.
本文引用的文献
1
Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.在脓毒性休克持续时间较长的患者中延长活化蛋白C治疗。
Intensive Care Med. 2009 Jul;35(7):1187-95. doi: 10.1007/s00134-009-1436-1. Epub 2009 Mar 5.
2
Recombinant human activated protein C, package labeling, and hemorrhage risks.重组人活化蛋白C、包装标签与出血风险。
Crit Care Med. 2009 Jan;37(1):327-9. doi: 10.1097/CCM.0b013e3181935102.
3
Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions.在严重脓毒症患者中使用活化蛋白C（drotrecogin alfa）及基线出血预防措施相关的不良结局。
Crit Care Med. 2009 Jan;37(1):19-25. doi: 10.1097/CCM.0b013e318192843b.
4
Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.一项关于活化蛋白C用于持续性感染性休克的多国安慰剂对照试验的设计、实施、分析及报告。
Intensive Care Med. 2008 Nov;34(11):1935-47. doi: 10.1007/s00134-008-1266-6. Epub 2008 Oct 7.
5
Human recombinant activated protein C for severe sepsis.用于严重脓毒症的重组人活化蛋白C
Cochrane Database Syst Rev. 2008 Jan 23(1):CD004388. doi: 10.1002/14651858.CD004388.pub3.
6
Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).在接受活化蛋白C治疗的严重脓毒症患者中预防性使用肝素。
Am J Respir Crit Care Med. 2007 Sep 1;176(5):483-90. doi: 10.1164/rccm.200612-1803OC. Epub 2007 Jun 7.
7
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.重组人活化蛋白C用于儿童严重脓毒症治疗：一项多中心III期随机对照试验
Lancet. 2007 Mar 10;369(9564):836-843. doi: 10.1016/S0140-6736(07)60411-5.
8
Can we RESOLVE the treatment of sepsis?我们能解决败血症的治疗问题吗？
Lancet. 2007 Mar 10;369(9564):803-804. doi: 10.1016/S0140-6736(07)60383-3.
9
Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.评估重组人活化蛋白C在成人严重脓毒症中的应用：一项加拿大多中心观察性研究。
Intensive Care Med. 2007 Mar;33(3):517-23. doi: 10.1007/s00134-007-0555-9. Epub 2007 Feb 15.
10
Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.意大利重症监护病房中活化蛋白C（重组人活化蛋白C）的使用情况：一项全国性调查的结果
Intensive Care Med. 2007 Mar;33(3):426-34. doi: 10.1007/s00134-007-0554-x. Epub 2007 Feb 15.
Zotero 插件